Compare WYETH LTD with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs NOVARTIS - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD NOVARTIS WYETH LTD/
NOVARTIS
 
P/E (TTM) x 27.7 908.8 3.1% View Chart
P/BV x 5.3 27.3 19.6% View Chart
Dividend Yield % 1.3 1.6 78.8%  

Financials

 WYETH LTD   NOVARTIS
EQUITY SHARE DATA
    WYETH LTD
Mar-13
NOVARTIS
Mar-19
WYETH LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,044980 106.6%   
Low Rs818600 136.3%   
Sales per share (Unadj.) Rs298.6198.7 150.2%  
Earnings per share (Unadj.) Rs57.221.0 273.0%  
Cash flow per share (Unadj.) Rs58.422.3 262.5%  
Dividends per share (Unadj.) Rs17.0010.00 170.0%  
Dividend yield (eoy) %1.81.3 144.2%  
Book value per share (Unadj.) Rs249.5307.5 81.1%  
Shares outstanding (eoy) m22.7224.69 92.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.0 78.5%   
Avg P/E ratio x16.337.7 43.2%  
P/CF ratio (eoy) x15.935.5 44.9%  
Price / Book Value ratio x3.72.6 145.3%  
Dividend payout %29.747.7 62.3%   
Avg Mkt Cap Rs m21,15719,508 108.5%   
No. of employees `0000.50.6 84.7%   
Total wages/salary Rs m4001,171 34.2%   
Avg. sales/employee Rs Th13,787.48,445.4 163.3%   
Avg. wages/employee Rs Th813.02,015.7 40.3%   
Avg. net profit/employee Rs Th2,643.3891.0 296.6%   
INCOME DATA
Net Sales Rs m6,7834,907 138.2%  
Other income Rs m353783 45.1%   
Total revenues Rs m7,1365,689 125.4%   
Gross profit Rs m1,617123 1,317.0%  
Depreciation Rs m2732 83.6%   
Interest Rs m616 34.6%   
Profit before tax Rs m1,938858 225.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m632340 185.9%   
Profit after tax Rs m1,301518 251.2%  
Gross profit margin %23.82.5 952.7%  
Effective tax rate %32.639.6 82.3%   
Net profit margin %19.210.6 181.7%  
BALANCE SHEET DATA
Current assets Rs m6,9848,055 86.7%   
Current liabilities Rs m2,0561,850 111.1%   
Net working cap to sales %72.6126.4 57.5%  
Current ratio x3.44.4 78.0%  
Inventory Days Days9945 220.5%  
Debtors Days Days2434 70.6%  
Net fixed assets Rs m244150 163.1%   
Share capital Rs m227123 184.1%   
"Free" reserves Rs m5,4417,469 72.8%   
Net worth Rs m5,6687,592 74.7%   
Long term debt Rs m250-   
Total assets Rs m7,9019,824 80.4%  
Interest coverage x353.354.9 643.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 171.9%   
Return on assets %16.55.4 304.3%  
Return on equity %22.96.8 336.5%  
Return on capital %34.011.5 295.9%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1558 26.4%   
Fx outflow Rs m2,6771,326 201.9%   
Net fx Rs m-2,662-1,269 209.8%   
CASH FLOW
From Operations Rs m923-1,943 -47.5%  
From Investments Rs m3172,742 11.6%  
From Financial Activity Rs m-481-298 161.3%  
Net Cashflow Rs m759501 151.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 75.0 68.1%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 7.2 1.6 450.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 21.5 141.4%  
Shareholders   21,978 41,647 52.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

CoronaVirus' Impact on Indian Markets - And One Stock With the Potential to Make Crores...(Profit Hunter)

Feb 7, 2020

Even as the experts come to grips with impact of Coronavirus contagion on Indian stocks and economy, here's a stock not just immune to macro threats, but with the potential to offer crores in the long term.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

A Megatrend to Help You Find the Best Stocks of the Next Decade(The 5 Minute Wrapup)

Feb 12, 2020

Recent events have put climate change into the spotlight. Here's how you should play this megatrend...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS